---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-221593"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2026-05-13T20:05:18+00:00"
generated_at: "2026-05-13T22:12:38.506705+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptevo reports 81% remission rate for mipletamig in frontline AML; $60M equity line secured

## Summary
- Mipletamig plus venetoclax/azacitidine: 87% clinical benefit rate, 81% CR/CRi, 65% CR in 31 evaluable patients; no CRS.
- RAINIER trial on track for completion and Phase 2 dose selection by year-end 2026.
- Q1 2026 cash position $14.5M; raised $0.9M net under SEPAs; secured new $60M SEPA with Yorkville.
- Jeff Lamothe appointed CEO; Marvin White transitions to Executive Chair.
- Leadership believes the $60M facility extends capital access into 2029 through key catalysts.

## SEC filing metadata
- accession: 0001193125-26-221593
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2026-05-13T20:05:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312526221593/0001193125-26-221593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312526221593/apvo-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-221593
- JSON: https://secwatch.observer/filing/0001193125-26-221593.json
- Plain text: https://secwatch.observer/filing/0001193125-26-221593.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.